Redeye comments on Cantargia's first quarter report 2026.
Fastighetsbolaget Trianons förvaltningsresultat per aktie ökade med 20 procent under det första kvar...
Rosenbauer published its Q1 figures, marked by double-digit improvements in top-line and bottom-line...
InvesteraMera ger en kommentar på licensavtalet för Idefirix mellan Hansa Biopharma och SERB Pharmac...
Hoenle published its Q2 FY25/26 results (covering Jan–Mar 2026) yesterday.
The report was below our estimates on sales, but we found ourselves above analyst consensus, which Q...
Kvartalet var något bättre än väntat på omsättning men något svagare vad gäller lönsamhet.
Redeye returns with a comment after the conference call on the EUR115m licensing deal yesterday.
* Volume growth in coming quarters * Growing verticals will likely add some costs * EV/EBIT of 10x '...
Redeye leaves a comment following ExpreS2ion’s announcement of updated Phase I progress and refineme...
• Cautious market climate hampers sales growth • Positive adjusted EBITDA and cash flow • We keep o...
Redeye provides a research update following the Q1 report recently published by Isofol.
We upgrade FLU to BUY. The shares have delivered nearly no return since our June 2023 Hold initiatio...
MAX published its Q1 2026 figures. These showcased a resilient performance in challenging market env...
Redeye comments on the licensing deal with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA.
Redeye returns with a research update on Sprint Bioscience following the Q1 report.
Redeye provides its initial take on Lagercrantz’s Q4 2025/2026 report, which beat our sales and EBIT...
Kentimas Q1-rapport var svagare än väntat med låg omsättningstillväxt och pressad lönsamhet till föl...
Redeye initiates coverage of 4C Group, a Swedish defence software company specialising in military e...
Redeye provides an update following Acarix’s Q1 2026 report, which showed revenues in line with esti...
